V. Bockstael and V. , Prevalence of multiple sclerosis in French farmers: a national survey, Multiple Sclerosis, vol.10, p.156, 2004.

J. Ingwersen, Fingolimod in multiple sclerosis: Mechanisms of action and clinical efficacy, Clinical Immunology, vol.142, issue.1, pp.15-24
DOI : 10.1016/j.clim.2011.05.005

. Fingolimod, Gilenya®) encore un immunosuppresseur dans le sclérose en plaques, Rev Prescire, vol.31, issue.330, pp.249-254, 2011.

G. Macé and . Pharmactua, Article du 05 janvier, 2011.

P. Durez and . La-polyarthrite-rhumatoïde, Brochure d'information à l'usage des patients, 2004.

J. Smolen, EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs, Annals of the Rheumatic Diseases, vol.69, issue.6, pp.1-12, 2009.
DOI : 10.1136/ard.2009.126532

B. Combe, The ESPOIR cohort: A ten-year follow-up of early arthritis in France, Joint Bone Spine, vol.74, issue.5, pp.440-445, 2007.
DOI : 10.1016/j.jbspin.2007.06.001

M. Kahn, Can we estimate the incidence, prevalence, and outcomes of rheumatoid arthritis in France?, Joint Bone Spine, vol.71, issue.2, pp.95-97, 2004.
DOI : 10.1016/j.jbspin.2003.10.005

P. Fan and K. Leong, The use of biological agents in the treatment of rheumatoid arthritis, Ann Acad Med Singapore, vol.36, pp.128-134, 2007.

J. Morel, Immunopathologie de la polyarthrite rhumatoïde, EMC-Rhumatologie Orthopédie, vol.2004, issue.1, pp.218-230
DOI : 10.1016/j.emcrho.2004.03.003

W. Grassi, The clinical features of rheumatoid arthritis, European Journal of Radiology, vol.27, issue.27, pp.18-24, 1998.
DOI : 10.1016/S0720-048X(98)00038-2

M. Chang and Y. Hsu, Interleukin-20 antagonist is a potential drug for rheumatoid arthritis, Arthritis Rheum, vol.54, issue.9, pp.2722-2733, 2006.

X. Mariette, Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry, Annals of the Rheumatic Diseases, vol.69, issue.2, pp.400-408, 2010.
DOI : 10.1136/ard.2009.117762

URL : https://hal.archives-ouvertes.fr/hal-00456934

J. Leombruno, The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events, Annals of the Rheumatic Diseases, vol.68, issue.7, pp.1136-1145, 2009.
DOI : 10.1136/ard.2008.091025

D. Wild, Infliximab Expected to Receive Approval For the Treatment of Ulcerative Colitis, p.7, 2005.

P. Heinrich, Principles of interleukin (IL)-6-type cytokine signalling and its regulation, Biochemical Journal, vol.374, issue.1
DOI : 10.1042/bj20030407

P. Heinrich, Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway, Biochemical Journal, vol.334, issue.2, pp.297-314, 1998.
DOI : 10.1042/bj3340297

S. Robert, Safety of biologic therapy in rheumatoid arthritis, Nature Reviews Rheumatology, vol.2011, issue.7, pp.639-652

A. Saraux, Prevalence of spondyloarthropathies in France: 2001, Annals of the Rheumatic Diseases, vol.64, issue.10, pp.1431-1435, 2001.
DOI : 10.1136/ard.2004.029207

J. Braun and J. Sieper, Ankylosing spondylitis, The Lancet, vol.369, issue.9570, pp.1379-1390, 2007.
DOI : 10.1016/S0140-6736(07)60635-7

URL : https://hal.archives-ouvertes.fr/hal-00503871

Y. Leung, Psoriatic arthritis as a distinct disease entity, Journal of Postgraduate Medicine, vol.53, issue.1, pp.63-71, 2007.
DOI : 10.4103/0022-3859.30334

D. Veale and O. Fitzgerald, Psoriatic arthritis, Best Practice & Research Clinical Rheumatology, vol.16, issue.4, pp.523-535, 2002.
DOI : 10.1016/S1521-6942(02)90248-2

. J. Braun and J. Sieper, Ankylosing spondylitis, The Lancet, vol.369, issue.9570, pp.1379-1390, 2007.
DOI : 10.1016/S0140-6736(07)60635-7

URL : https://hal.archives-ouvertes.fr/hal-00503871

M. Mansour, Ankylosing Spondylitis: A Contemporary Perspective on Diagnosis and Treatment, Seminars in Arthritis and Rheumatism, vol.36, issue.4, pp.210-223, 2007.
DOI : 10.1016/j.semarthrit.2006.08.003

A. Anandarajah and C. Ritchlin, Pathogenesis of psoriatic arthritis, Current Opinion in Rheumatology, vol.16, issue.4, pp.338-343, 2004.
DOI : 10.1097/01.bor.0000129718.13939.81<

D. Mcgonagle, Enthesitis: an autoinflammatory lesion linking nail and joint involvement in psoriatic disease, Journal of the European Academy of Dermatology and Venereology, vol.205, issue.Suppl. II, pp.9-13, 2009.
DOI : 10.1111/j.1468-3083.2009.03363.x

K. Nograles, New insights into the pathogenesis and genetics of psoriatic arthritis, Nature Clinical Practice Rheumatology, vol.437, issue.2
DOI : 10.1038/ncprheum0987

M. Rudwaleit, The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection, Annals of the Rheumatic Diseases, vol.68, issue.6
DOI : 10.1136/ard.2009.108233

M. Rudwaleit, New ASAS classification criteria for peripheral spondyloarthritis, ARD, vol.70, pp.25-31, 2011.

G. Melmed, Certolizumab pegol, Nature Reviews Drug Discovery, vol.371, issue.8, pp.641-644, 2008.
DOI : 10.1038/nrd2654

J. Hanke, Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor: STUDY OF Lck- AND FynT-DEPENDENT T CELL ACTIVATION, Journal of Biological Chemistry, vol.271, issue.2, pp.695-701, 1996.
DOI : 10.1074/jbc.271.2.695

M. Blaskovich, Discovery of JSI-124 (Cucurbitacin I), a selective janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice1, Cancer Research, vol.63, pp.1270-1279, 2003.

L. Vijayakrishnan, Treating inflammation with the Janus kinase inhibitor CP-690

R. Leischmann, Safety and efficacy after 24 week (wk) dosing of the oral JAK inhibitor CP-690,550 (CP) as monotherapy in patients (pts) with active rheumatoid arthritis (RA), Arthritis Rheum, vol.60, issue.10, p.1924, 2009.

I. Daïen, C. Et-morel, and J. , Implications dans la polyarthrite rhumatoïde, RéfleXions Rhumatologiques, vol.129, issue.14, 2010.

L. Lendrevie and . Lindon, Mercator. 9 ème édition
URL : https://hal.archives-ouvertes.fr/hal-00494894

M. Porter, Choix stratégiques et concurrence, Economica, vol.426

H. Mintzberg, The Strategy Process; concepts, context, cases. 4 th Editions

H. Itami and T. Et-roehl, Mobilizing invisible assets, 1987.

G. Johnson, 8 ème édition. Pearson Education, 2008.

A. Chandler, Stratégies et structures de l'entreprise, Ed. d'Organisation, 2006.

S. Floyd and W. Wooldridge, Building Strategy from the middle, 2000.

M. Porter, Competitive Strategy, techniques for analyzing industries and competitors. The Free Press, 1980.

J. Bain, Barriers to new Competition, 1956.
DOI : 10.4159/harvard.9780674188037

J. Bojin and J. Schoettl, Les outils de la stratégie

P. Vermersch, . La-sclérose-en-plaques-débutante, . Ed, L. John, and . Eurotext, 91 pages Sites Internet 11)http://www.nationalmssociety.org/about-multiple-sclerosis/what-we-know-about- ms/who-gets-ms/index.aspx. Consulté le 24)https://adpharm.net/blog/2011/03/rebif-delivered-through-innovation/ consulté le 23, 2008.